Navigation Links
Pharmaceutical Companies Lead Fight Against Staph and Other Infectious Diseases
Date:11/6/2007

WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -- A new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA) finds that America's pharmaceutical research companies are now testing 338 new medicines to help treat infectious diseases, including 11 medicines and four vaccines to treat staphococcal infections. This is particularly important in light of increased public concern about the spread of methicillin-resistant staphylococcus aureus (MRSA) infections -- a strain of staph that has become resistant to current treatments.

"Staph poses a serious pubic health threat that we are committed to fighting," PhRMA President and CEO Billy Tauzin said. "America's pharmaceutical research companies are working hard to develop new medicines that will treat staph and even prevent patients from infection in the first place."

Although scientists say infectious diseases will never be completely eliminated, new research and commitment of resources by both the government and pharmaceutical research companies can help meet the continuing - and ever-changing - threat from infectious diseases. These 338 medicines in development will help combat humankind's oldest and most tenacious enemy: infectious diseases.

Among the new medicines now being tested are 146 vaccines to prevent diseases such as smallpox and staph; 83 antibiotics/antibacterials to treat infections such as pneumonia and tuberculosis; 75 antivirals to treat such viruses as hepatitis and influenza; and, 25 antifungals.

According to the report, the medicines in development include:

--A first-in-class medicine designed specifically to inhibit drug-resistant strains of Staphylococcus aureus.

--A medicine for the treatment of hepatitis C that is part of a new class of drugs to regulate innate immunity.

--A medicine that stops the life cycle of the bacterium that causes tuberculosis.

Other medicines are in development for treatment of fu
'/>"/>

SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...th Hypophosphatasia Treated With ENB-0040 at Child... , , MONTREAL, Dec. 1 Enobi...used on developing novel therapeutics for serious ...ant patient in its clinical program for hypophosph...eplacement Therapy (ERT) with ENB-0040 for the tre...
(Date:12/1/2008)...D, Denmark, December 1 F...th the intent to procure an MVA-based,third gene...nt Services,Canada, on behalf of the Canadian Dep...ct to Bavarian Nordic for the delivery of IMVAMUNE...se IMVAMUNE(R) as part of the,country,s bio-prepa...
(Date:11/30/2008)...CHICAGO, Dec. 1 Older a...al blood flow and a greater number of small blood ...ted today at the annual meeting of the Radiologica... study, conducted at the University of North Caro...re brain scans of older adults who exercise to bra...
(Date:11/27/2008)...nds the majority of acute lymphoblastic leukemia r...the time of diagnosis , , MEMPHIS, Tenn., N.... Jude Children,s Research Hospital have identifie...of children with acute lymphoblastic leukemia (ALL... to designing treatments for ALL relapse in childr...
Breaking Medicine Technology:Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3SemBioSys eligible to proceed with Phase I II plant produced insulin trial after submission of IND 7709 1SemBioSys eligible to proceed with Phase I II plant produced insulin trial after submission of IND 7709 2SemBioSys eligible to proceed with Phase I II plant produced insulin trial after submission of IND 7709 3Intact Medical Corporations Intact 28R 29 Excise XL Receives 510 28K 29 Marketing Clearance from the FDA 7708 1Intact Medical Corporations Intact 28R 29 Excise XL Receives 510 28K 29 Marketing Clearance from the FDA 7708 2BioCryst to Present at UBS 2008 Global Life Sciences Conference 7703 1BioCryst to Present at UBS 2008 Global Life Sciences Conference 7703 2BioCryst to Present at UBS 2008 Global Life Sciences Conference 7703 3Althea Technologies Secures 2412 M Credit Line to Continue Facility Growth and Expansion 7701 1Althea Technologies Secures 2412 M Credit Line to Continue Facility Growth and Expansion 7701 2
...mic Societies, Annual Meeting,This Month in Toront...y Technology Can Reduce the Risk Associated with R...e/ -- Masimo, the,inventor of Pulse CO-Oximetry an...etry, reported that a new independent study,presen...ual Meeting,in Toronto, Canada earlier this month ...
...y 30, 2007 - People with a,class of rare genetic d... death can be successfully treated with drugs, say...f Medicine and Lucile,Packard Children,s Hospital....year study that,prompt diagnosis coupled with a ra...y improves the survival rates of people with,the c...
Other Medicine Technology:Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology,Shown to Significantly Lower Instances of Severe Retinopathy of,Prematurity in Extremely Low Birth Weight Infants 2Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology,Shown to Significantly Lower Instances of Severe Retinopathy of,Prematurity in Extremely Low Birth Weight Infants 3Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology,Shown to Significantly Lower Instances of Severe Retinopathy of,Prematurity in Extremely Low Birth Weight Infants 4Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard,Researcher 2Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard,Researcher 3Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard,Researcher 4
(Date:12/1/2008)...ding when their DNA is damaged, in a process known...DNA from leading to unregulated cell division and ...in this week,s issue of PLoS Biology , has found ...teins into their surrounding environment. This cau...rt the development of age-related diseases includi...
(Date:12/1/2008)...at Memorial Sloan-Kettering Cancer Center, New Yor...xpression of genes for therapeutic purposes, and u...n mice. , Small, noncoding RNA molecules known a...xpression. In the study, the miRNA miR-181a was ha... cells known as T cells at different stages of the...
(Date:12/1/2008)...all/ - The Westaim Corporation today announced it ...s of NUCRYST Pharmaceuticals Corp. to consider a r...imately US$15 million or US$0.80 per share. Westai... the value of its 74.5 per cent stake in NUCRYST. ...ST,s Board of Directors has 20 days to call a meet...
(Date:12/1/2008)...- Media entrepreneur, television and,radio host R...ropist John,Bendheim will be honored by the Cedar...To A Cure" Gala, December 2, 2008, at the Hyatt Re... of the Board of Governors, co-chairs the,event w...olomon. The "Road To,A Cure" Gala is sponsored b...
Breaking Medicine News(10 mins):Health News:Escape cancer, but age sooner? The dark side of the tumor suppressing process 2Health News:The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders 2Health News:Cedars-Sinai Board of Governors to Honor Ryan Seacrest & John Bendheim at Annual 'Road To A Cure' Gala 2
...looks like Jessica Simpson is desperate to stun pe...tress reportedly shed around 11.3 kilograms in one...ne of 1,300-calorie-a-day, set by her celeb traine... she even got him to deliver the nutritional meals...
...en, across the globe, use a vast range of cosmetic...use is leading to a chemical pile up in their bodi...-up every day are soaking up nearly 5lb of chemica...dies. Many use over 20 different beauty products p...
...ording to a new report in the New England Journal ... drug entecavir can cause those who are also infe...st important drugs in the anti-HIV arsenal. the ...ected with both hepatitis B and HIV who was treate...
...earch study at University of Alberta ,shows a st...ence how elderly rural Albertans with congestive h...values may delay them from seeking help at critica...iew their work as a lifelong endeavour, and there ...
Other Medicine News:Health News:Excessive Use of Cosmetics Leads to Adverse Effects on the Body 2Health News:Challenges in Entecavir Drug Treatment 2Health News:Rural Work Ethic Curbs Elderly Heart Care 2
...Med TruFlow™ Oxygen flowmeter with a Lexan&r...nty covering calibration and manufacturing defects...meet most needs. Also available with all popular i...f and double unit configurations. Our extra large ...
...ates to adults, the entire series of time-tested T...surpassed knowledge of the needs of care providers...y. You can see it in the craftsmanship. You can se...meter® Classic Flowmeter is hand-crafted and e...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value.
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value.
Medicine Products: